Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Baxter
Moodys
Express Scripts

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR HALOPERIDOL DECANOATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Haloperidol Decanoate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018642 ↗ Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder Completed US Department of Veterans Affairs N/A 1997-04-01 The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
NCT00018642 ↗ Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder Completed VA Office of Research and Development N/A 1997-04-01 The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
NCT00947375 ↗ Lamictal TM, Haloperidol Decanoate in Schizophrenia Terminated Central Mental Clinic for Outpatients of Baku City Phase 4 2005-01-01 The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study. Nadir A.Aliyev & Zafar N.Aliyev Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic Abstract: OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Haloperidol Decanoate

Condition Name

Condition Name for Haloperidol Decanoate
Intervention Trials
Schizophrenia 4
Schizoaffective Disorder 2
Subsyndromal Delirium 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Haloperidol Decanoate
Intervention Trials
Schizophrenia 5
Psychotic Disorders 4
Mental Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Haloperidol Decanoate

Trials by Country

Trials by Country for Haloperidol Decanoate
Location Trials
United States 20
Nigeria 1
Azerbaijan 1
Tanzania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Haloperidol Decanoate
Location Trials
Texas 2
California 2
Ohio 2
Michigan 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Haloperidol Decanoate

Clinical Trial Phase

Clinical Trial Phase for Haloperidol Decanoate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Haloperidol Decanoate
Clinical Trial Phase Trials
Completed 5
Unknown status 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Haloperidol Decanoate

Sponsor Name

Sponsor Name for Haloperidol Decanoate
Sponsor Trials
National Institute of Mental Health (NIMH) 2
Case Western Reserve University 2
Central Mental Clinic for Outpatients of Baku City 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Haloperidol Decanoate
Sponsor Trials
Other 10
NIH 5
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Harvard Business School
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.